Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betaprodine SCHEMBL25053 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL186644 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Alphaprodine SCHEMBL25054 | 1.00 | LMNA (0.97) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL394431 | 0.99 | LMNA (1.00) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Alphaprodine SCHEMBL8818643 | 0.99 | LMNA (1.00) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL1649307 | 0.97 | LMNA (0.93) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Proheptazine SCHEMBL25539 | 0.93 | LMNA (0.84) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL11383571 | 0.89 | LMNA (0.78) | LMNADRD3NPSR1OPRM1OPRD1 | |
| Betaprodine SCHEMBL4283575 | 0.88 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 | |
| SCHEMBL8977860 | 0.88 | LMNA (0.77) | LMNADRD3NPSR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1036 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440489-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240343784-A1 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H LUNDBECK AS (DK) | 2024-10-17 | — | — | US | claimed |
| US-20240165111-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| US-11844757-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | claimed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | claimed |
| US-20230181576-A9 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-06-15 | — | — | US | claimed |
| US-11527315-B2 | Drug device configured for wireless communication | POP TEST ABUSE DETERRENT TECHNOLOGY LLC (US) | 2022-12-13 | — | — | US | claimed |
| WO-2011099985-A1 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN | LEIDER HARRY (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195520-A1 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN | AMERITOX, LTD. (US) | 2011-08-11 | — | — | US | claimed |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-07-29 | — | — | US | claimed |
| EP-1758452-A4 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | HUMAN BIOMOLECULAR RES INST (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1758452-A1 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | Human Biomolecular Research Institute (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060136023-A1 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | MARVIN, ROBERT | 2006-06-22 | — | — | US | claimed |
| WO-2005117589-A1 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2005-12-15 | — | — | WO | claimed |
| US-6869440-B2 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | INNERCOOL THERAPIES, INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20030060863-A1 | Method and apparatus for patient temperature control employing administration of anti-shivering agents | ZOLL CIRCULATION, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2003015672-A1 | METHOD AND APPARATUS FOR PATIENT TEMPERATURE CONTROL EMPLOYING ADMINISTRATION OF ANTI-SHIVERING | INNERCOOL THERAPIES, INC. (US) | 2003-02-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11527315-B2 | Drug device configured for wireless communication | CYP2D6, CYP2B6, PTGDR | LMNA 3860/4885DRD3 420/4885NPSR1 19/4885 |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | LMNA 4517/4885DRD3 549/4885NPSR1 66/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | LMNA 3289/4885DRD3 19/4885NPSR1 21/4885 |
| US-20240165111-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR3A | LMNA 4582/4885DRD3 32/4885NPSR1 120/4885 |
| US-20230181576-A9 | ORGANIC COMPOUNDS | OPRD1, OPRK1, OPRM1 | LMNA 4028/4885DRD3 30/4885NPSR1 60/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | LMNA 3133/4885DRD3 19/4885NPSR1 27/4885 |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | OPRK1, OPRL1, OPRM1 | LMNA 4221/4885DRD3 817/4885NPSR1 9/4885 |
| US-11844757-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | LMNA 4028/4885DRD3 30/4885NPSR1 60/4885 |
| US-12440489-B2 | Organic compounds | OPRD1, OPRK1, OPRM1 | LMNA 4028/4885DRD3 30/4885NPSR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.